|
Countermeasures Against Chemical Threats (CounterACT) Research Network Annual Symposium
|
Meeting/ Workshop
|
CDC, FDA, OS
|
NINDS, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, OD
|
This workshop was organized by NINDS as part of the Countermeasures Against Chemical Threats (CounterACT) Research Network, a group formed to conduct basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic and diagnostic medical countermeasures against chemical threat agents. The 3-day meeting allowed researchers to share information, encouraged collaboration, and enabled NIH staff to evaluate the group’s progress on themes such as nerve agents, seizure detection technology, cyanide, and sulfur mustard.
|
|
Crafting Integrated Chronic Disease Strategies Using System Dynamics
|
Training Initiative
|
ACF, CDC, HRSA, OS, SAMHSA
|
OD, NHLBI, NICHD, NIDDK, NLM
|
A one-day educational workshop to provide public health officials with an introduction to system dynamics modeling for research and practice.
|
|
Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone, National Hormone and Pituitary Program (NHPP)
|
Resource Development
|
CDC, FDA
|
NIDDK
|
"From 1963 to 1985, the National Hormone and Pituitary Program (NHPP), funded by the U.S. Department of Health and Human Services (HHS), sent hGH (human growth hormone) made from human pituitary glands to hundreds of doctors across the country. As a part of research studies, doctors used the hormone to treat nearly 7,700 children for failure to grow.
In 1985, the HHS learned that three people treated with pituitary hGH died of CJD (Creutzfeldt-Jakob Disease), a rare, incurable brain disease. The HHS immediately stopped distributing the hormone and began a national study to learn more about how pituitary hGH treatment may have caused this problem.
"
|
|
Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS)
|
Research Initiative
|
SAMHSA
|
NIDA
|
Research network seeking to determine the best way to integrate evidence-based drug abuse treatment into criminal justice settings including practices related to screening and assessment, HIV intervention, and medication assisted treatment for opioid dependence.
|
|
DailyMed
|
Other
|
FDA
|
NLM
|
DailyMed provides high quality information about marketed drugs, including FDA labels (package inserts). The Web site provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. NLM provides this DailyMed a public service, free of advertising.
|
|
Data Access for Grantees
|
Resource Development
|
CMS
|
NIA
|
NIA developed this MOU to assist grantees with accessing CMS data. It is anticipated that this initiative will create a more user friendly and more cost efficient means for grantees to access CMS data especially the need to access Part D data. Specifically, this MOU gives CMS''s Privacy Board justification to release Part D data to NIA grantees with Data Use Agreements. Researchers pay for data use.
|
|
Data Mining on FDA''s 510K Documents for Laboratory Tests
|
Research Initiative
|
FDA
|
NLM
|
U.S. Food and Drug Administration (FDA) provides a large corpus of text about decision summaries on the applications for in vitro diagnostic (laboratory) products. This corpus of text contains valuable information about the nature of laboratory testing devices and test products such as analyte and specimen names that are tested, unit of measures, and analyte detection limits of the presented devices and products. In this project NLM is trying to recognize and extract this information algorithmically and provide them to the operators who are responsible to collect this information and enter it into the LOINC database manually.
|
|
Data Sample and CMS Link for the National Health and Aging Trends Study
|
Research Initiative
|
CMS
|
NIA
|
This collaboration is designed to provide a sample and to link CMS data to participants who consent to participate in the National Health and Aging Trends Study (NHATS). NHATS will exam how the daily lives of older adults change as they age. This research will help scientists understand the social and economic consequences of late-life disability for individuals, families, and society.
|
|
Defining Appropriate Outcome Measures for Older Persons with Multiple Chronic Conditions
|
Meeting/ Workshop
|
AHRQ
|
NIA
|
Inter-Agency Agreement between Agency for Healthcare Research & Quality and National Institute on Aging, NIH. The purpose of this Inter-Agency Agreement (IAA) is to authorize the transfer of funds appropriated for the Agency for Healthcare Research and Quality (AHRQ) to the National Institute on Aging (NIA/NIH), in order to support an expert panel meeting, as well as products and activities resulting from this event, that will assess the current state of available metrics for individuals with multiple chronic conditions, prioritize usable measures based upon stakeholder needs, and foster the development or refinement of additional promising outcome measures. The findings from this event should have broad applicability and uptake in research, clinical care, and program evaluation efforts to improve the health of the population burdened by multiple chronic conditions.
|
|
Demand Reduction Interagency Working Groups
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
To encourage greater cross-talk and Agency participation in developing the National Drug Control Strategy, ONDCP reconstituted its demand reduction workgroups focusing on prevention, emerging threats, healthcare delivery, justice systems, military veterans and their families, and performance and accountability measures. NIDA staff have participated in all of these working groups.
|